Loeb & Loeb LLP is proud to sponsor the American Conference Institute’s 4th Annual Paragraph IV Disputes Conference: Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics, where partner Mark Waddell is a speaker.
From the conference website:
Now in its fourth year, ACI’s Paragraph IV Disputes conference has become the most trusted source for the ‘ins and outs’ of Paragraph IV litigation. This first and original conference of its kind serves as the litigation playbook for brand name and generic drug companies in the high-stakes arena of Hatch-Waxman litigation.
The inherent intensity of Paragraph IV litigation has been magnified of late by the seemingly unending repercussions of the Hatch-Waxman reforms of the MMA, pending Patent Reform legislation, the imminent approval of an abbreviated pathway for follow-on biological products and the threat of proposed legislation, which may make settlements of these matters near impossible — let alone illegal. These factors have all added to the complexity of this litigation, and have also raised the monetary ante to unprecedented heights.